Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

This partnership will enable Cipla arm (Breathe Free Lanka) to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of Chronic Obstructive Pulmonary Disease (COPD). As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.

Colombo: A subsidiary of Cipla, Breathe Free Lanka Pvt Ltd (“Breathe Free Lanka”), recently announced a partnership with Novartis for the marketing and distribution of Novartis’ Ultibro Breezhaler.

This partnership will enable Cipla arm (Breathe Free Lanka) to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of Chronic Obstructive Pulmonary Disease (COPD). As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.

This development is in line with Cipla’s aim of addressing unmet patient needs in respiratory and other therapy areas in Sri Lanka. The company has a strong record of focusing its efforts on improving healthcare and enhancing access to innovative medicines for improved disease management and better quality of life, especially for patients who currently do not have easy access to critical medicines.

Also Read: Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat a diabetic foot ulcer

Commenting on the same, Nishant Saxena, CEO, International Business (Europe & Emerging Markets), Cipla said, “As market leaders with significant presence in the respiratory segment, we look forward to leveraging our marketing and distribution strengths in Sri Lanka to take this product to as many patients as possible in furtherance of our purpose of ‘Caring for Life’.”

Celine Landie, Managing Director, Singapore & Asian Emerging Markets, Novartis said, “Our partnership with Cipla is aligned with the Novartis commitment to address the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices.”

Breathe Free Lanka Pvt Ltd, a wholly-owned subsidiary of Cipla, was born out of the vision of making quality medicines accessible to patients across Sri Lanka.

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The company is a player in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments.